



NEWS RELEASE

Pfizer Limited revenues (net of transition support sales) increased by 7% for the quarter and 8% for the half year ended September 30, 2014

- **Pfizer Ltd and Wyeth Ltd Scheme of Amalgamation approved by Bombay High court**

November 6, 2014, Mumbai: Pfizer Ltd announced its results for the Second quarter and half year ended September 30, 2014.

The revenue for the second quarter was ₹269 crore (Q2 2013-14 ₹267 crore) and for the half year was ₹509 crore (Half year 2013-14 ₹505 crore) reflecting a growth of 1% each respectively.

The financial results are not strictly comparable as last year periods include the transition support for sales of certain animal health products. Excluding these transactions, the revenues for the quarter was ₹269 crore (Q2 2013-14 ₹252 crore) and for the half year was ₹509 crore (Half year 2013-14 ₹470 crore) reflecting a growth of 7% and 8% respectively.

Profit from operation (before other income and tax) for the quarter is ₹48 crore (Q2 2013-14 ₹72 crore) and for the half year was ₹108 crore (Half year 2013-14 ₹115 crore). Profits are lower due to higher expenses incurred in the current quarter on account of advertisement expenses and other onetime expenses aggregating to ₹21 crore.

Other Income for the quarter is lower by ₹24 crore primarily due to lower interest income post payment of interim dividend of ₹360 per share last year.

The company had announced a voluntary retirement scheme during the quarter at its Plant in Thane. Expenses in relation to VRS and other related costs (₹76 crore) have been reflected as Exceptional items.

Consequently, Profit after tax for the Quarter reflects a loss ₹12 crore (Q2 2013-14 profit ₹46 crore) and for the half year was ₹34 crore (Half year 2013-14 ₹117 crore).

Recently, the Hon'ble High Court of Judicature at Bombay on October 31, 2014 considered and approved the amalgamation of Wyeth Limited with the Company, in terms of the Scheme of Amalgamation.

Contacts -

Investors:

Prajeet Nair

Pfizer Ltd

Ph: +91-22-66932352

Email: prajeet.nair@pfizer.com

Media:

Sherry Varghese

Pfizer Ltd

Ph: +91-9619914505

Email: sherry.varghese@pfizer.com

**About Pfizer Ltd:**

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people. Every day, Pfizer colleagues work to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 60 years in India, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizerindia.com

Disclaimer

The information contained in this press release is only current as of its date. All actions and statements made herein or otherwise shall be subject to the applicable laws and regulations as amended from time to time. There is no representation that all information relating to the context has been taken care of in the press release and neither we undertake any obligation as to the regular updating of the information as a result of new information, future events or otherwise. We will accept no liability whatsoever for any loss arising directly or indirectly from the use of, reliance of any information contained in this press release or for any omission of the information. The information shall not be distributed or used by any person or entity in any jurisdiction or countries where such distribution or use would be contrary to the applicable laws or Regulations. It is advised that prior to acting upon this press release, independent consultation / advice may be obtained and necessary due diligence, investigation etc. may be done at your end.